Nervous Disorder TRIZ Cases

Reelin agonists activate ApoER2 and VLDLR receptors to restore synaptic plasticity disrupted by Alzheimer's pathology.

A GPPGPAG peptide sequence enhances dendritic and presynaptic density in neural cells to improve memory recognition.

Purified cannabidiol at 5-50 mg/kg/day treats treatment-resistant epilepsy by reducing tonic-clonic and absence seizures in CHRNA4 mutation patients.

Acid-washed housing removes aggregating metals from Interferon-beta solutions, preventing protein aggregation and maintaining bioavailability.

Fc fusion proteins sequester excess endothelin-1 via high-affinity binding, resolving the trade-off between physiological signaling and tissue pathology.

Template-fixed beta-hairpin peptidomimetics overcome low oral bioavailability and cytotoxicity of conventional inhibitors through composite material design.

Combining gabapentin with lysine clonixinate produces synergistic analgesic effects through distinct neurotransmission modulation.

Targeting STOML3 in sensory neurons blocks touch receptor function, reversing mechanical hypersensitivity while avoiding central nervous system side effects.

Standardized cognitive assessments predict treatment response to anti-SEMA4D therapy, resolving diagnostic complexity and patient selection heterogeneity.

Segmented delayed-release formulations transport nutrients to the colon, resolving low Dialister spp. levels linked to chronic disorders.

Metal chloride crosslinks the pressure-sensitive adhesive layer to stabilize cohesiveness and prevent adhesive transfer during removal.

Merging CD22 and CD3 targeting into one molecule resolves the trade-off between single-target efficacy and complex combination regimens.

A resectin protein fragment demonstrates novel extracellular signaling activity distinct from canonical aminoacylation functions.

Linking two G-CSF monomers via a peptide connector creates a dimer that reduces administration frequency while maintaining therapeutic efficacy.

Bicyclic heteroaryl compounds inhibit phosphodiesterase 4 activity, resolving the trade-off between therapeutic efficacy and adverse side effects.

Albumin-amyloid peptide conjugates induce anti-amyloid antibodies to reduce serum amyloid beta levels.

Low-concentration ethanol extraction yields a bean extract that reduces cholesterol and prevents cardiovascular disease side effects.

SARM1 inhibitors block NADase activity within the catalytic pocket, preventing NAD+ depletion that drives axonal degeneration.

Selective radioligand binding removes toxic amyloid beta aggregates without depleting physiological monomers, preventing neuronal impairment.

Humanized and chimeric TNF-α binding proteins resolve the trade-off between binding affinity and manufacturing complexity through targeted parameter changes.

Segmented tablet design combines enteric-coated aspirin core with vonoprazan outer layer to prevent gastric ulcers while maintaining antiplatelet efficacy.

BD-AcAc2 administration maintains therapeutic ketosis levels for several hours, preventing seizures during hyperbaric oxygen exposure.

Theogallin and quinic acid alter EEG frequencies to treat dementia while reducing side effects.

A transdermal patch incorporates diflucortolone valerate into the adhesive layer to deliver therapeutic drugs while protecting skin tissue.

Segmented siRNA molecules evade nonspecific immune responses while delivering sustained gene silencing in neurodegenerative disease models.

Targeted mass spectrometry resolves non-specific antibody binding by measuring characteristic fragmentation patterns of pathological TDP-43 fragments.

Removing CpG dinucleotides from the FXN gene prevents methylation silencing and restores reliable frataxin expression.

Formula I pyridines and pyrazines inhibit class III PTK receptors like FMS and c-KIT to treat kinase-associated diseases.

Extracellular vesicles from cardiosphere-derived cells reduce senescence and extend telomere length to treat age-related heart dysfunction.

Asymmetric siRNA compounds apply localized chemical modifications to reduce immune response while maintaining nuclease resistance.

Amino acid sequences bind HER2 receptors to inhibit signaling pathways, overcoming low efficacy in tumors with low HER2 expression.

Fusing a cell-penetrating peptide to the botulinum toxin light chain enables transdermal delivery, bypassing injection toxicity and liver damage.

3-hydroxybutyl 3-hydroxybutyrate elevates blood ketone levels via controlled hydrolysis, avoiding the acidosis caused by direct free acid administration.

A statistical threshold method identifies clinically significant immune responses to therapeutic proteins using control population data.

Excipient-mediated formulation improves cannabidiol bioavailability to slow neurodegeneration and manage Parkinson's disease symptoms.

C1-esterase inhibitor targets complement activation to prevent relapses and reduce cumulative disability in neuromyelitis optica spectrum disorders.

New chemical structures overcome triclabendazole resistance in Fasciola hepatica while maintaining efficacy against juvenile worms.

Multi-extract herbal composition reduces neuronal cell death and oxidative stress, addressing inadequate standard therapies for neurodegenerative disorders.

Interleukin-15 administration reduces myocardial scarring and enhances cardiac remodeling in ischemic conditions.

SNAC carriers improve water solubility and gastrointestinal penetration of plant-based compounds, reducing onset time and increasing bioavailability.

Specific amino acid substitutions in the hIL-2 mutein induce regulatory T cells while reducing systemic toxicity.

Catfish epidermal gel soluble protein fraction promotes axonal and myelin regeneration to address inadequate peripheral nerve injury recovery.

Urine metabolite biomarkers identify autism spectrum disorder risk via UPLC-MS/MS, replacing subjective behavioral assessments with objective diagnostic data.

Isolating the (-)-stereoisomer of 2,6-di-sec-butylphenol reduces hemodynamic effects and injection pain compared to propofol.

Sodium chlorite composition reduces monocyte activation and inflammatory protein production in brain tissue.

Novel peptides stimulate anti-tumor immune responses by binding to MHC molecules and presenting tumor antigens to T cells.

Monovalent domain antibodies block CD28 interactions with CD80 and CD86, resolving the trade-off between binding affinity and CTLA4 cross-reactivity.

Merges cannabidiol and brivaracetam to treat treatment-resistant epilepsy, reducing atonic and tonic-clonic seizures.

Endogenous Muse cells reverse organ fibrosis by regenerating functional tissue without immune rejection risks.